Empagliflozin may decrease risk of kidney stones in diabetics

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-06-14 04:30 GMT | Update On 2022-06-14 07:58 GMT

We all know that Empagliflozin is the drug used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes. It is also used to reduce the risk of stroke, heart attack, or death in people who have type 2 diabetes along with heart and blood vessel disease. Also, empagliflozin is used in adults with heart failure to reduce the risk of needing to be hospitalized and death due to heart and blood vessel disease.

Now, this diabetes drug has been found to decrease the risk of kidney stones in patients with type 2 diabetes.

Researchers used existing data from 20 randomized clinical trials to evaluate whether empagliflozin reduced the risk of kidney stones and they pooled data from 15,081 type 2 diabetes patients. Of these, 10,177 received empagliflozin and 4,904 received a placebo.

Patients took either empagliflozin or a placebo for about 1 ½ years. The results of the study showed that when compared with placebo, treatment with empagliflozin was associated with an approximate 40% reduced risk of kidney stones in type 2 diabetes patients. While the precise mechanism is not known, the findings did mean that empagliflozin may be used to prevent kidney stones in individuals with type 2 diabetes.

This study was presented Sunday, June 12 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Empagliflozin may decrease risk of kidney stones in diabetics

Similar News

AI Model May Accurately Predict Kidney Failure Risk in Chronic Kidney Disease Patients: Study Shows

Journal Club- Infection Patterns and Survival Among Renal Transplant Recipients

Alarming Growth in Antifungal Resistance Tracked Over 30 Years in Dutch Study

COVID-19 Vaccination Reduces Dialysis and Mortality Risk in Acute Kidney Injury Patients: Study

Study Reveals Why Your Immune System Works Better in Daylight

World's First Human Bladder Transplant Successfully Performed by USC and UCLA Surgeons

Trial Shows Tirzepatide May Benefit People with Obesity, Kidney Disease and Heart Failure

Breakthrough in Kidney Health: New Biomarkers Enhance Early Detection and Monitoring, Study Shows